目的 探索脂必妥片联合阿昔莫司胶囊治疗高脂血症的临床效果。方法 选取2024年1月—11月在首都医科大学附属北京康复医院及北京市门头沟区中医医院接受治疗的高脂血症患者110例，使用信封随机分组技术将患者分为对照组（55例）和治疗组（55例）。对照组口服阿昔莫司胶囊，2～3次/d，1粒/次，治疗组在对照组基础上口服脂必妥片，3片/次，2次/d，两组患者治疗2个月。观察两组患者临床疗效，比较治疗前后两组患者临床症状好转时间，血脂总胆固醇（TC）、三酰甘油（TG）、低密度脂蛋白（LDL-C）和高密度脂蛋白（HDL-C）水平，及血液流变学指标全血高切黏度、全血低切黏度、全血黏度、血浆黏度和纤维蛋白原水平。结果 治疗后，治疗组总有效率为94.55%，明显高于对照组的81.82%（P＜0.05）。治疗后，治疗组患者临床症状好转时间显著短于对照组（P＜0.05）。治疗后，两组患者TC、TG和LDL-C水平均显著低于治疗前（P＜0.05），且治疗组的血脂改善效果明显优于对照组（P＜0.05）。治疗后，治疗组患者全血高切黏度、全血低切黏度、血浆黏度及纤维蛋白原水平显著低于治疗前水平（P＜0.05）。同时，治疗组患者血液流变学指标水平明显低于对照组（P＜0.05）。结论 脂必妥片联合阿昔莫司胶囊治疗高脂血症临床疗效显著，能够改善临床症状和血脂水平，调节血液流变学指标，且用药安全性高。

Objective To explore the clinical efficacy of Zhibituo Tablets combined with acipimox in treatment of hyperlipidemia. Methods Patients (110 cases) with hyperlipidemia in Beijing Rehabilitation Hospital Affiliated to Capital Medical University and Beijing Mentougou District Hospital of Traditional Chinese Medicine from January 2024 to November were randomly divided into control (55 cases) and treatment (55 cases) group. Patients in the control group were po administered with Acipimox Capsules, 2 — 3 time/d, 1 grains/time. Patients in the treatment group were po administered with Zhibituo Tablets on the basis of the control group, 3 tablets/time, twice daily. Patients in two groups were treated for 2 months. After treatment, the clinical evaluations were evaluated, and the clinical symptom relief time, and the levels of blood lipid TC, TG, LDL-C and HDL-C, and the hemorheological indicators of whole blood high shear viscosity, whole blood low shear viscosity, whole blood viscosity, plasma viscosity and fibrinogen in two groups before and after treatment were compared. Results After treatment, the total effective rate of patients in the treatment group was 94.55%, which was significantly higher than 81.82% in the control group (P < 0.05). After treatment, the improve time of clinical symptoms in the treatment group was significantly shorter than that in the control group (P < 0.05). After treatment, the levels of TC, TG and LDL-C in two groups were significantly lower than those before treatment (P < 0.05), and the improvement effect of blood lipids in the treatment group was significantly better than that in the control group (P < 0.05). After treatment, the whole blood high shear viscosity, whole blood low shear viscosity, plasma viscosity and fibrinogen levels in the treatment group were significantly lower than those before treatment (P < 0.05). At the same time, the levels of hemorheology indicators in the treatment group were significantly lower than that in the control group (P < 0.05). Conclusion The combination of Zhibituo Tablets and Axiolimus Capsules has significant clinical efficacy in treating hyperlipidemia, improving clinical symptoms and blood lipid levels, regulating hemorheological indicators, and high safety.

R973

首都卫生发展科研专项（首发2024-2G-2251）